08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

AureoGen Biosciences, Merck deal

AureoGen granted Merck exclusive rights to develop and commercialize preclinical derivatives of aureobasidin A to treat infectious disease, including systemic fungal infections. Merck will also have exclusive rights to additional derivatives generated using AureoGen’s chemistry...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Company News

AureoGen Biosciences, Takara Bio deal

AureoGen received non-exclusive rights to develop and commercialize Takara’s antifungal compound aureobasidin A and related antibiotics. AureoGen also received rights to Aureobasidium pullulans, the organism that produces the cyclic peptide. All licensed compounds are in...